Compare 3-D Matrix Ltd. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Operating profit has grown by an annual rate 15.58% of over the last 5 years
- The company is Net-Debt Free
2
Poor long term growth as Operating profit has grown by an annual rate 15.58% of over the last 5 years
3
The company has declared Positive results for the last 5 consecutive quarters
4
With ROE of 24.57%, it has a very attractive valuation with a 8.42 Price to Book Value
5
Majority shareholders : FIIs
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 43,766 Million (Small Cap)
34.00
NA
0.00%
-0.29
24.57%
8.45
Revenue and Profits:
Net Sales:
3,225 Million
(Quarterly Results - Jul 2026)
Net Profit:
303 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.93%
0%
24.93%
6 Months
2.13%
0%
2.13%
1 Year
29.82%
0%
29.82%
2 Years
268.38%
0%
268.38%
3 Years
178.06%
0%
178.06%
4 Years
40.39%
0%
40.39%
5 Years
51.23%
0%
51.23%
3-D Matrix Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
60.32%
EBIT Growth (5y)
15.58%
EBIT to Interest (avg)
-152.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
1.16
Tax Ratio
22.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0.86%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
8.42
EV to EBIT
267.88
EV to EBITDA
267.88
EV to Capital Employed
11.52
EV to Sales
4.57
PEG Ratio
0.16
Dividend Yield
NA
ROCE (Latest)
4.30%
ROE (Latest)
24.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jul 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jul'26 - YoY
Jul'26
Jul'25
Change(%)
Net Sales
3,225.30
2,194.90
46.95%
Operating Profit (PBDIT) excl Other Income
495.00
9.50
5,110.53%
Interest
5.10
9.80
-47.96%
Exceptional Items
-2.20
-20.50
89.27%
Consolidate Net Profit
303.00
765.60
-60.42%
Operating Profit Margin (Excl OI)
153.40%
4.30%
14.91%
USD in Million.
Net Sales
YoY Growth in quarter ended Jul 2026 is 46.95% vs 47.75% in Jul 2025
Consolidated Net Profit
YoY Growth in quarter ended Jul 2026 is -60.42% vs 197.23% in Jul 2025
Annual Results Snapshot (Consolidated) - Apr'26
Apr'26
Apr'25
Change(%)
Net Sales
10,886.30
6,934.10
57.00%
Operating Profit (PBDIT) excl Other Income
1,335.80
-1,156.20
215.53%
Interest
18.00
74.40
-75.81%
Exceptional Items
180.50
4.60
3,823.91%
Consolidate Net Profit
4,155.90
-2,501.20
266.16%
Operating Profit Margin (Excl OI)
122.70%
-166.70%
28.94%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2026 is 57.00% vs 51.11% in Apr 2025
Consolidated Net Profit
YoY Growth in year ended Apr 2026 is 266.16% vs -878.94% in Apr 2025
About 3-D Matrix Ltd. 
3-D Matrix Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






